Dermorphin

Dermorphin was isolated from the skin of South American Phyllomedusa tree frogs and was one of the first natural peptides found to contain a D-amino acid — D-alanine at position 2 — which is what protects it from rapid aminopeptidase degradation and gives it its potency. It binds the mu opioid receptor with subnanomolar affinity and far greater mu-over-delta selectivity than morphine. Given centrally in animals it is reported to be on the order of thirty to forty times more potent than morphine on a molar basis; given peripherally the potency advantage shrinks because it crosses the blood-brain barrier poorly for a molecule of its potency. Everything downstream is standard mu pharmacology: analgesia, sedation, respiratory depression, constipation, tolerance and dependence. It became publicly notorious around 2012 when it was detected in racehorses in the United States as an undetectable-looking analgesic, which is where the nickname 'frog juice' comes from.

Targets: Mu opioid receptor (OPRM1), Descending antinociceptive pathways

• · There is no human dose for dermorphin. None has ever been published, and the compound is thirty-plus times morphine's potency, which means the margin between an analgesic dose and a fatal respiratory depressant dose is a matter of a few hundred micrograms of estimation error. Anyone quoting a dermorphin protocol invented it.

Work out your exact syringe units →

• very commonRespiratory depression— This is the realistic mechanism of death. It is dose-dependent and, at this potency, close to the analgesic dose.
• very commonProfound sedation
• very commonTolerance and physical dependence— Full mu agonism with a fast onset is the classic recipe for both.
• very commonNausea, vomiting and constipation
• commonPruritus and histamine-type flushing

• Any concurrent opioid, benzodiazepine, gabapentinoid, alcohol or other CNS depressant — additive respiratory depression is what actually kills people with mu agonists.
• Sleep apnoea, COPD or any condition with reduced respiratory reserve.
• Any situation without naloxone immediately on hand and a second person present. Naloxone does reverse dermorphin, but the peptide may outlast a single dose of naloxone.
• Competitive sport of any kind — it is a WADA-prohibited substance and the reason equine anti-doping added it to screening panels.

• redundantdalda — Both are dermorphin-family mu agonists; stacking them multiplies respiratory risk and adds nothing.
• redundantendomorphin-1-and-2 — Same receptor, same risk, no additional benefit.
• cautionenkephalins — Overlapping opioid tone; enkephalinase-inhibitor strategies are pointless alongside a full exogenous mu agonist.

• · There is no monitoring protocol because there is no legitimate human use. If someone has taken it, the only relevant monitoring is respiratory rate, oxygen saturation and level of consciousness.

Not approved for human or veterinary use in the US or EU. Prohibited at all times by WADA and by horse-racing authorities. As a potent mu opioid agonist it plausibly falls under controlled-substance analogue provisions in several jurisdictions, so possession is not necessarily the legal grey area that 'research peptide' framing implies.

• Montecucchi et al. 1981, isolation of dermorphin from Phyllomedusa sauvagei skin (preclinical)
• Broccardo et al., pharmacological profile of dermorphin at the mu opioid receptor (preclinical)

The pharmacology here is not mysterious — it is standard mu opioid agonism with the volume turned up. Dermorphin binds OPRM1 with subnanomolar affinity and a mu-over-delta selectivity far higher than morphine's, and it is a full agonist with no ceiling. Downstream it is textbook: Gi/Go coupling, adenylyl cyclase inhibition, GIRK potassium channel opening on postsynaptic neurons, N-type calcium channel closure on presynaptic terminals, and disinhibition of the descending antinociceptive pathway from the periaqueductal grey through the rostral ventromedial medulla. That last piece is where the analgesia mostly comes from. What is worth understanding is why the D-alanine matters so much. Native opioid peptides are destroyed by aminopeptidase N cleaving the Tyr1-Gly2 bond within seconds to minutes, which is why enkephalins are useless as drugs. Replacing Gly2 with D-Ala makes the bond unrecognisable to the enzyme, and what you get is not a more potent receptor ligand so much as a ligand that survives long enough to reach the receptor and stay there. Central potency thirty to forty times morphine on a molar basis follows from that combination of high intrinsic affinity and survival. Two things do not follow, and both are dangerous to assume. First, dermorphin's poor blood-brain barrier penetration means the systemic potency ratio is much smaller and much less predictable than the central one — so scaling a rodent intracerebroventricular dose to a human subcutaneous dose by any arithmetic gives a wrong answer. Second, full mu agonism at high efficacy is exactly the receptor profile that produces respiratory depression, and there is no evidence of any bias in dermorphin's signalling that would separate analgesia from apnoea. The endomorphin analogue programme spent two decades looking for that separation; dermorphin was never claimed to have it. It also carries a histamine-releasing cationic character, which is why pruritus and flushing show up. Naloxone reverses it, as it reverses any mu agonist, but naloxone's half-life is around an hour and a peptide that outlives it will re-sedate the patient after the reversal wears off — the standard re-narcotisation problem, and a serious one when the agonist's duration is not known.

The single thing that goes wrong is respiratory depression, and the reason it goes wrong with dermorphin specifically is arithmetic. A compound thirty to forty times morphine's molar potency means the difference between an analgesic dose and a lethal one is measured in a few hundred micrograms of estimation error, from a powder that people weigh on jewellery scales and reconstitute by eye. There is no published human dose to anchor against, so every quoted protocol is invention — if you find a dermorphin dosing chart, someone made it up, and they made it up for a molecule where being wrong by a factor of three is fatal. Layered on top: the systemic-versus-central potency gap means a dose that does nothing when you take it may still be a large central dose once enough has crossed, which produces the classic 'nothing is happening so I'll take more' escalation into a delayed overdose. Naloxone reverses it, but naloxone has a one-hour half-life and dermorphin's human duration is unknown, so re-narcotisation after apparent recovery is a realistic scenario and one dose of naloxone is not enough of a plan. Tolerance and physical dependence develop as they do with any full mu agonist with fast onset — this is the classic reinforcement profile, and the fact that it is a 'research peptide' rather than a pill changes nothing about that. Finally, the sporting and legal dimension is not a footnote: dermorphin is WADA-prohibited at all times, it is screened for in equine anti-doping because of the 2012 racehorse cases, and as a potent mu opioid agonist it plausibly falls under controlled-substance analogue provisions in multiple jurisdictions. 'Research peptide' is not the legal shield people assume it is.

• Mu opioid receptor (OPRM1) — Subnanomolar, with mu-over-delta selectivity substantially greater than morphine's. Specific Ki values are reported throughout the preclinical literature but I did not resolve a primary source for them in this session, so no number is asserted.

  Full agonism. Gi/Go coupling, adenylyl cyclase inhibition, GIRK opening, presynaptic calcium channel closure, activation of descending inhibition from the periaqueductal grey. Reported as roughly thirty to forty times more potent than morphine on a molar basis when given centrally in animals.

• Delta and kappa opioid receptors — Very low relative to mu — dermorphin is one of the most mu-selective natural opioid peptides known.

  Essentially none at analgesic exposure. The selectivity is why dermorphin has been used for decades as a laboratory tool for probing mu-specific effects.

• Brainstem respiratory centres — pre-Bötzinger complex mu receptors — Same receptor, same full agonism.

  Respiratory rate depression. This is the mechanism of death with any full mu agonist and there is nothing about dermorphin that mitigates it. The safety margin is narrower than morphine's precisely because the potency is higher and the human dose is unknown.

• Mast cells — non-receptor, cationic — Not receptor-mediated.

  Histamine release producing pruritus and flushing, the same phenomenon seen with morphine and with other cationic peptides.

Minutes after parenteral administration in animal models, with the caveat that everything about the human timeline is unknown. The practical hazard is the mismatch between the peripheral and central curves: subjective effects lag the injection while the peptide slowly crosses the blood-brain barrier, so the peak central effect can arrive well after someone has concluded the dose was too small. Duration in animals is on the order of tens of minutes to a couple of hours, longer than the native enkephalins because of the D-Ala2 protection but far shorter than morphine. No human onset, peak or duration figures exist.

There is no legitimate stack that includes dermorphin, and the honest version of this section is a list of things that will kill you faster. Any second CNS depressant — another opioid, a benzodiazepine, a gabapentinoid, alcohol, an antihistamine, a Z-drug — is additive on respiratory drive, and combined depressant use is what actually kills people with mu agonists rather than the agonist alone. Stacking with DALDA or the endomorphins is pharmacologically redundant (same receptor, no additional mechanism) and additive on risk. Stacking with difelikefalin is incoherent: kappa agonism opposes mu-mediated reward, so you get the respiratory risk of the mu agonist with the dysphoria of the kappa agonist and less of what either was supposed to provide. Enkephalinase-inhibitor strategies, which work by raising endogenous enkephalin tone at sites of release, are pointless in the presence of a flooding exogenous full agonist. And the one combination worth naming positively: naloxone, in the room, unexpired, with someone awake who knows how to use it.

The instructive comparison is with everything else on this list that shares the mu receptor. The endomorphin analogue programme spent two decades trying to build a mu agonist whose analgesia separated from respiratory depression, tolerance and reward, and produced rodent compounds that appeared to do it. Oliceridine took the same biased-signalling hypothesis all the way to FDA approval and delivered a marginal real-world advantage over morphine. Difelikefalin took a different route entirely — different receptor, engineered to stay out of the brain — and got a label. Dermorphin has none of that. It is a natural product with high potency, high selectivity and no dissociation of any kind between the effect you want and the effect that kills you. It is genuinely important scientifically: the discovery of a D-amino acid in an animal peptide rewrote assumptions about ribosomal synthesis and post-translational modification, and dermorphin remains a standard laboratory mu agonist. It is not, and has never been, a candidate for human use. The gap between 'well-characterised in rats' and 'safe in people' is exactly the gap that ziconotide and difelikefalin closed with phase 3 programmes and dermorphin never even entered.

Deliberately not priced. Dermorphin is sold as a research powder in milligram quantities and there is no human dose, so a monthly cost figure would imply a use pattern that does not exist and should not be constructed. This is a laboratory reagent and a doping agent, not a compound with a monthly protocol.

• ?No human pharmacokinetics of any kind exist: no half-life, no volume of distribution, no clearance, no protein binding, no bioavailability by any route.
• ?The 'thirty to forty times morphine' potency figure comes from animal central-administration studies reported in the secondary literature; I did not resolve a primary source for it in this session and the ratio varies substantially between assays and routes.
• ?No Ki values at mu, delta or kappa are asserted, because I did not verify a primary source for them.
• ?Blood-brain barrier penetration is described as partial and poor-for-its-potency based on the secondary literature; there is no quantitative human or primate brain-penetration figure.
• ?Duration of action in humans is completely unknown, which is the specific reason the re-narcotisation risk after naloxone cannot be quantified.
• ?The legal analysis (controlled-substance analogue provisions) is jurisdiction-dependent and was not verified against specific statutes in this session.

• Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei Montecucchi PC, de Castiglione R, Piani S, et al., International Journal of Peptide and Protein Research, 1981 · PMID 7287299

  The original isolation and sequencing paper. This is where Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 comes from, and it is historically important as one of the first demonstrations that an animal peptide can contain a D-amino acid.